Advances in immune therapy may change how scientists and clinicians understand neurodegenerative components of MS.
By Thomas Leist, MD, PhD
At the Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference, experts revealed encouraging new directions in treating and understanding PD.
By Ted Pigeon, Editor-in-Chief
Physicians should consider a range of both pharmacologic and non-pharmacologic interventions when addressing agitation.
A Q&A with Jeffrey Cummings, MD, ScD
One expert addresses the evolving standards of care and strategies for enabling patients to receive optimal care.
A Q&A with David M. Simpson, MD
Amid the many technological advances in recent years, robotic laser thermotherapy has emerged as a new approach in treating brain tumors.
A Q&A with Joseph Neimat, MD
An investigational agent under study for the treatment of neuropsychiatric disorders as well as a rare genetic disorder offers a glimpse of a new stage in neurological therapy.
With Josephine Elia, MD and Donna M. McDonald-McGinn, MS, CGC
In addition to comorbid conditions and side effects, cost and availability should factor into therapeutic selection.
This second in a two-part feature series on marijuana addresses the potential benefits of medical marijuana in neurology and considers future directions in care.
By Ronald Devere, MD
An understanding of the basic science, clinical presentation, and treatment options for neuralgic amyotrophy is necessary to facilitate timely diagnosis and treatment.
By John W. Norbury, MD, Nens van Alfen, MD, PhD, Kelly M. Harrell, PhD, MPT, Carrie A. McShane, MD, Daniel P. Moore, MD, Steven Mandel, MD
LLCs and FLPs can be fundamental tools for business planning, asset protection planning, family wealth planning, estate planning, and more.